anywherellka.blogg.se - Totally legal sapphire for after effects

Motor Function Score (HFMSE) ≥10 and ≤45 at Screening.

If receiving the SMN upregulator therapy risdiplam, must have completed at least 6 months of dosing before Screening.

If receiving the SMN upregulator therapy nusinersen, must have completed at least 10 months of dosing (i.e., completed the loading regimen and at least 2 maintenance doses) before Screening.

Receiving one background therapy for SMA (i.e., either nusinersen or risdiplam) for the time period specified below and anticipated to remain on that same treatment throughout the trial: Nonambulatory patients must be able to sit independently (sits up straight with head erect for at least 10 seconds does not use arms or hands to balance body or support position) per World Health Organization (WHO) motor milestones definition at Screening.

Diagnosed with later-onset SMA (i.e., Type 2 and Type 3 SMA) before receiving an approved SMN upregulator therapy (i.e., either nusinersen or risdiplam).Males and females 2 through 21 years old at Screening.Main Efficacy Population and Exploratory Subpopulation combined: Presence or absence of ADA against apitegromab in serum from blood samples.

Main Efficacy Population and Exploratory Subpopulation combined: Circulating latent myostatin concentrations in blood samples.Main Efficacy Population and Exploratory Subpopulation combined: Apitegromab concentrations in serum from blood samples.Main Efficacy Population and Exploratory Subpopulation combined: Incidence of Treatment Emergent Adverse Events (TEAEs) and Severe Adverse Events (SAEs) by severity.Main Efficacy Population: Change from Baseline in number of WHO motor development milestones attained at 12 months.Higher scores increased great upper limb function. The 19 scored items assess functions that relate to everyday life, such as pressing a button and picking up a token these items are scored 0, 1, or 2, where 0 denotes unable, 1 denotes able with modification, and 2 denotes able with no modification. The RULM is a 20 item assessment of upper limb function in nonambulatory patients with SMA that was performed for patients who were 30 months of age or older at baseline. Why Should I Register and Submit Results?.